Literature DB >> 23071356

c-Myc and cancer metabolism.

Donald M Miller1, Shelia D Thomas, Ashraful Islam, David Muench, Kara Sedoris.   

Abstract

The processes of cellular growth regulation and cellular metabolism are closely interrelated. The c-Myc oncogene is a "master regulator" which controls many aspects of both of these processes. The metabolic changes which occur in transformed cells, many of which are driven by c-Myc overexpression, are necessary to support the increased need for nucleic acids, proteins, and lipids necessary for rapid cellular proliferation. At the same time, c-Myc overexpression results in coordinated changes in level of expression of gene families which result in increased cellular proliferation. This interesting duality of c-Myc effects places it in the mainstream of transformational changes and gives it a very important role in regulating the "transformed phenotype." The effects induced by c-Myc can occur either as a "primary oncogene" which is activated by amplification or translocation or as a downstream effect of other activated oncogenes. In either case, it appears that c-Myc plays a central role in sustaining the changes which occur with transformation. Although efforts to use c-Myc as a therapeutic target have been quite frustrating, it appears that this may change in the next few years. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23071356      PMCID: PMC3505847          DOI: 10.1158/1078-0432.CCR-12-0977

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  100 in total

1.  On respiratory impairment in cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-08-10       Impact factor: 47.728

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

3.  Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.

Authors:  Masayoshi Yada; Shigetsugu Hatakeyama; Takumi Kamura; Masaaki Nishiyama; Ryosuke Tsunematsu; Hiroyuki Imaki; Noriko Ishida; Fumihiko Okumura; Keiko Nakayama; Keiichi I Nakayama
Journal:  EMBO J       Date:  2004-04-22       Impact factor: 11.598

4.  Design and properties of a Myc derivative that efficiently homodimerizes.

Authors:  L Soucek; M Helmer-Citterich; A Sacco; R Jucker; G Cesareni; S Nasi
Journal:  Oncogene       Date:  1998-11-12       Impact factor: 9.867

Review 5.  Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling.

Authors:  Livnat Jerby; Eytan Ruppin
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

6.  Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts.

Authors:  L Lombardi; E W Newcomb; R Dalla-Favera
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

7.  Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements.

Authors:  Arvind Ramanathan; Connie Wang; Stuart L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-19       Impact factor: 11.205

8.  Transcriptional repression: the dark side of myc.

Authors:  Barbara Herkert; Martin Eilers
Journal:  Genes Cancer       Date:  2010-06

Review 9.  Rethinking the Warburg effect with Myc micromanaging glutamine metabolism.

Authors:  Chi V Dang
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

10.  The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry.

Authors:  Fionnuala Morrish; Nicola Neretti; John M Sedivy; David M Hockenbery
Journal:  Cell Cycle       Date:  2008-02-08       Impact factor: 4.534

View more
  250 in total

1.  A Positive Feedback Loop Between c-Myc Upregulation, Glycolytic Shift, and Histone Acetylation Enhances Cancer Stem Cell-like Property and Tumorigenicity of Cr(VI)-transformed Cells.

Authors:  Marco Clementino; Jie Xie; Ping Yang; Yunfei Li; Hsuan-Pei Lin; William K Fenske; Hua Tao; Kazuya Kondo; Chengfeng Yang; Zhishan Wang
Journal:  Toxicol Sci       Date:  2020-09-01       Impact factor: 4.849

Review 2.  Signal transduction in cancer.

Authors:  Richard Sever; Joan S Brugge
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

3.  Interleukin-1β Activates a MYC-Dependent Metabolic Switch in Kidney Stromal Cells Necessary for Progressive Tubulointerstitial Fibrosis.

Authors:  Dario R Lemos; Michael McMurdo; Gamze Karaca; Julia Wilflingseder; Irina A Leaf; Navin Gupta; Tomoya Miyoshi; Koichiro Susa; Bryce G Johnson; Kirolous Soliman; Guanghai Wang; Ryuji Morizane; Joseph V Bonventre; Jeremy S Duffield
Journal:  J Am Soc Nephrol       Date:  2018-05-08       Impact factor: 10.121

4.  Emodin elicits cytotoxicity in human lung adenocarcinoma A549 cells through inducing apoptosis.

Authors:  Wing-Yan Li; Yam-Fung Ng; Huan Zhang; Zi-Dong Guo; De-Jian Guo; Yiu-Wa Kwan; George Pak-Heng Leung; Simon Ming-Yuen Lee; Peter Hoi-Fu Yu; Shun-Wan Chan
Journal:  Inflammopharmacology       Date:  2013-08-22       Impact factor: 4.473

5.  HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer.

Authors:  Debarati Banik; Satish Noonepalle; Melissa Hadley; Erica Palmer; Maria Gracia-Hernandez; Christian Zevallos-Delgado; Namratta Manhas; Hayk Simonyan; Colin N Young; Anastas Popratiloff; Katherine B Chiappinelli; Rohan Fernandes; Eduardo M Sotomayor; Alejandro Villagra
Journal:  Cancer Res       Date:  2020-06-30       Impact factor: 12.701

Review 6.  Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

Authors:  Nissim Hay
Journal:  Nat Rev Cancer       Date:  2016-09-16       Impact factor: 60.716

Review 7.  How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?

Authors:  H Lincet; P Icard
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

8.  RIZ1 negatively regulates ubiquitin-conjugating enzyme E2C/UbcH10 via targeting c-Myc in meningioma.

Authors:  Zheng Cai; Yongxiang Zou; Hongkang Hu; Chengyin Lu; Wei Sun; Lei Jiang; Guohan Hu
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

9.  Halogenated diarylacetylenes repress c-myc expression in cancer cells.

Authors:  Vitaliy M Sviripa; Wen Zhang; Liliia M Kril; Alice X Liu; Yaxia Yuan; Chang-Guo Zhan; Chunming Liu; David S Watt
Journal:  Bioorg Med Chem Lett       Date:  2014-05-09       Impact factor: 2.823

Review 10.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.